Our top pick for
FTI Consulting Inc is a consulting services business based in the US. FTI Consulting shares (FCN) are listed on the NYSE and all prices are listed in US Dollars. FTI Consulting employs 6,411 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$145.01|
|52-week range||$95.79 - $147.38|
|50-day moving average||$137.34|
|200-day moving average||$139.79|
|Wall St. target price||$179.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$6.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||1.90%|
|1 month (2021-09-20)||8.29%|
|3 months (2021-07-20)||6.03%|
|6 months (2021-04-20)||-0.51%|
|1 year (2020-10-19)||27.83%|
|2 years (2019-10-18)||29.45%|
|3 years (2018-10-19)||114.51%|
|5 years (2016-10-19)||233.43%|
Valuing FTI Consulting stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of FTI Consulting's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
FTI Consulting's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, FTI Consulting shares trade at around 24x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
FTI Consulting's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into FTI Consulting's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
FTI Consulting's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $367.7 million.
The EBITDA is a measure of a FTI Consulting's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.6 billion|
|Operating margin TTM||12.35%|
|Gross profit TTM||$788.6 million|
|Return on assets TTM||7.24%|
|Return on equity TTM||1570.18%|
|Market capitalisation||$4.9 billion|
TTM: trailing 12 months
There are currently 1.4 million FTI Consulting shares held short by investors – that's known as FTI Consulting's "short interest". This figure is 9.2% down from 1.6 million last month.
There are a few different ways that this level of interest in shorting FTI Consulting shares can be evaluated.
FTI Consulting's "short interest ratio" (SIR) is the quantity of FTI Consulting shares currently shorted divided by the average quantity of FTI Consulting shares traded daily (recently around 187468.93840105). FTI Consulting's SIR currently stands at 7.63. In other words for every 100,000 FTI Consulting shares traded daily on the market, roughly 7630 shares are currently held short.
However FTI Consulting's short interest can also be evaluated against the total number of FTI Consulting shares, or, against the total number of tradable FTI Consulting shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case FTI Consulting's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 FTI Consulting shares in existence, roughly 40 shares are currently held short) or 0.0441% of the tradable shares (for every 100,000 tradable FTI Consulting shares, roughly 44 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against FTI Consulting.
Find out more about how you can short FTI Consulting stock.
We're not expecting FTI Consulting to pay a dividend over the next 12 months.
FTI Consulting's shares were split on a 3:2 basis on 4 June 2003. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your FTI Consulting shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for FTI Consulting shares which in turn could have impacted FTI Consulting's share price.
Over the last 12 months, FTI Consulting's shares have ranged in value from as little as $95.79 up to $147.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while FTI Consulting's is 0.4302. This would suggest that FTI Consulting's shares are less volatile than average (for this exchange).
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. Its Corporate Finance & Restructuring segment provides business transformation, transactions, turnaround, restructuring, and bankruptcy services. The company's Forensic and Litigation Consulting segment offers anti-corruption/anti-money laundering investigations and compliance, and data and analytics, as well as compliance, monitoring, and receivership services; cybersecurity, forensic accounting and advisory, and global risk and investigations practice; and construction solutions, dispute advisory, trial, insurance claims, health and environmental solutions, and export controls and sanctions. Its Economic Consulting segment provides financial, economic, and econometric consulting; business and expert valuation, and expert testimony services; intellectual property services; economic and statistical analyses services; services related to public policy and regulated industries, and healthcare economics and policy; international arbitration; and economic impact analysis, market modeling, and securities litigation and risk management services and other litigation services. The company's Technology segment offers e-discovery and data compliance management, managed document review, digital forensics, information governance, privacy and security, and contract intelligence services, as well as Radiance Visual Analytics software. Its Strategic Communications segment provides advice services relating to public affairs and government relations, crisis communications, corporate reputation, digital and, capital markets communications, transaction communications, and digital, analytics, and insights.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.